Infinity Pharmaceuticals
Advent contact Shahzad Malik
Company CEO Adelene Q. Perkins
Chemical genomic
based drug discovery
Chemical genomic based drug discovery
Infinity (NASDAQ: INFI) has a therapeutic focus in oncology and is seeking to develop medicines for difficult-to-treat diseases. Infinity is developing a range of small molecule drugs that target emerging disease pathways.
- Follow Infinity Pharmaceuticals
- infi.com